Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells 12,694 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Hyong Kim sold 12,694 shares of Alignment Healthcare stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $237,885.56. Following the completion of the transaction, the insider owned 349,639 shares in the company, valued at $6,552,234.86. The trade was a 3.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Hyong Kim also recently made the following trade(s):

• On Thursday, October 9th, Hyong Kim sold 51,379 shares of Alignment Healthcare stock. The shares were sold at an average price of $17.57, for a total value of $902,729.03.
• On Wednesday, October 8th, Hyong Kim sold 33,655 shares of Alignment Healthcare stock. The stock was sold at an average price of $17.29, for a total transaction of $581,894.95.

Alignment Healthcare Stock Performance

ALHC stock traded up $0.30 on Tuesday, reaching $19.24. 2,308,291 shares of the company were exchanged, compared to its average volume of 3,029,631. The firm has a market capitalization of $3.85 billion, a PE ratio of -160.33 and a beta of 1.16. Alignment Healthcare, Inc. has a 12 month low of $11.01 and a 12 month high of $21.06. The stock’s fifty day moving average price is $18.18 and its 200 day moving average price is $16.19. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The company had revenue of $993.70 million during the quarter, compared to the consensus estimate of $980.90 million. During the same quarter last year, the company earned ($0.14) EPS. The company’s quarterly revenue was up 43.5% on a year-over-year basis. On average, research analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Alignment Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after purchasing an additional 6,940,277 shares during the last quarter. Invesco Ltd. raised its stake in shares of Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after acquiring an additional 2,294,739 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Alignment Healthcare by 173.3% during the second quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock worth $28,556,000 after purchasing an additional 1,293,416 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Alignment Healthcare by 61.0% during the third quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock valued at $55,775,000 after purchasing an additional 1,210,930 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its holdings in shares of Alignment Healthcare by 300.0% in the third quarter. Integral Health Asset Management LLC now owns 1,600,000 shares of the company’s stock valued at $27,920,000 after purchasing an additional 1,200,000 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. KeyCorp reaffirmed an “overweight” rating on shares of Alignment Healthcare in a report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, October 8th. Wall Street Zen upgraded Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reiterated a “buy” rating and set a $22.00 price objective on shares of Alignment Healthcare in a research note on Monday, November 3rd. Finally, UBS Group lifted their price objective on Alignment Healthcare from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.35.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.